Summary

KEY FINDINGS
The Asia-Pacific botulinum toxin market is projected to grow with a 10.19% CAGR between the forecast years 2023 and 2032. Growing preference for non-surgical aesthetic treatments, the popularity of botulinum toxin treatments among facelift patients, including minimal discomfort, reduced downtime, and lasting effects, is further expected to boost the market growth.
MARKET INSIGHTS
The Asia-Pacific botulinum toxin market growth analysis includes the analysis of Singapore, Australia & New Zealand, South Korea, Japan, India, Thailand, China, and Rest of Asia-Pacific. South Korea has emerged as one of the top markets for cosmetic procedures worldwide, with the sector’s revenue estimated to be $10 billion. Several factors, such as medical tourism, high-tech products, rising awareness, and an aging population, propel the market growth.
Botox injections are expected to grow considerably due to South Korea’s aging population, where nearly 40% of the population will be over 65 by 2060. Additionally, migraine sufferers are increasing in South Korea, leading to a surge in demand for botulinum toxin for chronic migraine treatment. Organizations like the Korean Headache Society are actively working to help those suffering from migraines. The demand for botulinum toxin for cosmetic purposes in South Korea is also high.
In Singapore, the prevalence of migraine is high, causing significant economic losses. Hence, market players have the opportunity to establish themselves in the country. Singapore imports most of its Botulinum toxin from India and is the second-largest importer of the product globally. Apart from medical use, botulinum toxin is increasingly used in cosmetic procedures in Singapore. These market trends indicate a growing demand for botulinum toxin in Asia-Pacific.
COMPETITIVE INSIGHTS
Leading market players entails Lanzhou Institute of Biological Products Co Ltd, Merz Pharma, Medytox, Daewoong Pharmaceutical Co Ltd, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON BOTULINUM TOXIN MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. FAVORABLE REGULATORY APPROVALS ADD TO MARKET GROWTH
2.5.2. GROWING AWARENESS ABOUT ‘NOTOX’
2.5.3. INFLATING COSMETIC TOURISM ADDS TO THE DEMAND FOR BOTULINUM TOXIN
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN DEMAND FOR AESTHETIC PROCEDURES
3.1.2. RISING GERIATRIC POPULATION
3.1.3. GROWING DEMAND FOR NON-INVASIVE COSMETIC PROCEDURES
3.2. KEY RESTRAINTS
3.2.1. CONCERNS REGARDING THE ADVERSE EFFECTS OF BOTULINUM TOXIN
3.2.2. LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR CHINA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY TYPE
5.1. TYPE A BOTULINUM TOXIN
5.2. TYPE B BOTULINUM TOXIN
6. MARKET BY USER DEMOGRAPHIC
6.1. WOMEN
6.2. MEN
7. MARKET BY APPLICATION
7.1. MEDICAL
7.1.1. CHRONIC MIGRAINE
7.1.2. MUSCLE SPASM
7.1.3. OVERACTIVE BLADDER
7.1.4. HYPERHIDROSIS
7.1.5. OTHER MEDICAL APPLICATIONS
7.2. AESTHETIC
7.2.1. CROW’S FEET
7.2.2. FOREHEAD LINES
7.2.3. FROWN LINES/GLABELLAR
7.2.4. SQUARE JAW/MASSETER
7.2.5. OTHER AESTHETIC APPLICATIONS
8. MARKET BY END-USER
8.1. SPECIALTY AND DERMATOLOGY CLINICS
8.2. HOSPITALS AND CLINICS
8.3. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. ASIA-PACIFIC BOTULINUM TOXIN MARKET DRIVERS
9.1.3. ASIA-PACIFIC BOTULINUM TOXIN MARKET CHALLENGES
9.1.4. ASIA-PACIFIC BOTULINUM TOXIN MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN ASIA-PACIFIC BOTULINUM TOXIN MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. CHINA
9.1.6.1.1. CHINA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.2. JAPAN
9.1.6.2.1. JAPAN BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.3. INDIA
9.1.6.3.1. INDIA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.4. SOUTH KOREA
9.1.6.4.1. SOUTH KOREA BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.5. SINGAPORE
9.1.6.5.1. SINGAPORE BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.6. THAILAND
9.1.6.6.1. THAILAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.7. AUSTRALIA & NEW ZEALAND
9.1.6.7.1. AUSTRALIA & NEW ZEALAND BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
9.1.6.8. REST OF ASIA-PACIFIC
9.1.6.8.1. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS
10.1.4. BUSINESS EXPANSIONS
10.2. COMPANY PROFILES
10.2.1. ABBVIE
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. CANDELA MEDICAL
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. DAEWOONG PHARMACEUTICAL CO LTD
10.2.3.1. COMPANY PROFILE
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. EVOLUS INC
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. GALDERMA
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. HUGEL INC
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. IPSEN
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS / SERVICES LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO LTD
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCT LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. MEDYTOX INC
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. MERZ PHARMA
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCT LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. REVANCE THERAPEUTICS INC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.12. US WORLDMEDS LLC
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCT LIST